The Evolving Role of Genotypic Data

Ruben A. Mesa, MD

Video Categories: Myelofibrosis

Dr. Mesa recognizes that although genotypic data is not yet being used to select treatment choice or dosing in myelofibrosis, it is used to address the issues of prognosis and burden of disease.
March 31, 2015

Ibrutinib and ABT199 for CLL

Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.

July 25, 2018

New Clinical Trial Data in Advanced Melanoma Presented at ASCO 2018: How Will it Change How You Practice?

Dr Sanjiv Agarwala talks about exciting new results presented at ASCO 2018 in melanoma, including the durability of anti–PD-1 therapy in providing 40% overall survival at 5 years, updates on adjuvant therapy showing superiority of anti–PD-1 over anti–CTLA-4, and new results in combining immunotherapies.